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Abstract 
The enteric nervous system (ENS) is an integrative 
neuronal network, organized in two ganglionated plexuses, 
myenteric and submucosal, composed of neurons and 
enteric glial cells, controlling the activity of the smooth 
muscle of the gut, mucosal secretion and blood flow. The 
ENS contains as many neurons as the spinal cord, and the 
functional and chemical diversity of enteric neurons 
closely resembles that of the central nervous system. This 
highly integrated neural system is also referred to as the 
‘brain-in-the-gut’, because of its capability to function in 
the absence of nerve inputs from the central nervous 
system.  
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 The ENS controls gut motility and secretion via 
local reflexes that are triggered by local distension of 
the intestinal wall, distortion of the mucosa, and 
chemical contents in the lumen. This neuronal 
regulation of GI functions is due to the liberation of 
specific neuromediators synthesized by functionally 
defined enteric neurons. In addition, ENS is involved 
in the control of immune and inflammatory processes 
throughout the gut. Thus, it is not surprising that any 
damage to ENS circuitries and in the neurotransmitters 
systems results in a wide array of gut disorders, 
including motor impairments, which are characterized 
by high morbidity. In the future, challenges are to 
properly understand the molecular and cellular 
changes that underlie enteric neuropathies, to utilize 
knowledge of the normal neurochemistry, 
pharmacology and physiology of the ENS to devise 
strategies to treat disorders of motility and to develop 
effective therapeutic compounds. 
 
Introduction 
The enteric nervous system (ENS) may be defined as 
the system of neurons and their supporting cells (glia) 
that is found within the walls of the gastrointestinal 
tract, including the pancreas and gall bladder.  An 
“enteric neuron” is any neuron whose cell body is 
within the ENS.  The enteric nervous system regulates 
gastrointestinal functions including motility, secretions, 
blood flow, and the immune system. It is unique in its 
ability to function independently of the central nervous 
system (CNS) in the control of the functions of the 
digestive tract. For this reason, the ENS is considered 
to be a “second brain in the gut”.1 However, the CNS 
is able to modulate, but not entirely control, the GI 
function by sending instructions via the two 
components of the extrinsic autonomic nervous 
system: the sympathetic and parasympathetic nervous 
system. 
 
The CNS and the ENS share a common origin and 
have functional and chemical similarities: i) the ENS 
in fact derives from neural crest cells that migrate to 
the cranial portion of the gut and subsequently move 
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caudally to reach the entire GI tract; ii) the ENS contains a 
number of neurons similar to those found in the spinal cord 
(approximately 80–100 million neurons); iii) ENS express 
all neurotransmitters so far known in CNS (more than 30 
neurotransmitters). These include classical 
neurotransmitters such as acetylcholine (Ach), 
noradrenaline, serotonin, GABA and glutamate, but a great 
number of other neurotransmitter and hormones also 
participate in the regulation of functions in the GI tract: 
vasoactive intestinal polypeptide (VIP), nitric oxide, 
galanin, motilin, adenosine triphosphate, tachykinins, ecc.; 
iv) the ENS is an integrative neural network including 
afferent neurons, interneurons, and efferent neurons; v) the 
enteric glial cells are remarkably like astrocytes in 
structure and biochemistry and a diffusion barrier around 
the capillaries surrounding ganglia, similar to the cerebral 
blood-brain barrier.  
 
The ENS is organized in two ganglionated plexuses, 
myenteric and submucosal, composed of neurons and 
enteric glial cells. The myenteric plexus (or Auerbach’s 
plexus)  lies between the external longitudinal and internal 
circular muscle layers. The submucosal plexus (or 
Meissner’s plexus) lies between the circular muscle layer 
and the mucosa. Neurons of the myenteric plexus control 
the activity of the smooth muscle of the gut, whereas those 
in the submucosal plexus regulate mucosal secretion and 
blood flow. The ENS controls gut motility and secretion 
via local reflexes that are triggered by local distension of 
the intestinal wall, distortion of the mucosa, and chemical 
contents in the lumen. These reflexes involve parallel 
circuits of synaptically interconnected ENS neurons, 
which include primary intrinsic afferent neural cells, 
ascending and descending interneurons, excitatory and 
inhibitory motorneurons, vasomotorneurons and 
secretomotorneurons. For example, in the myenteric 
plexus, activation of ascending interneurons and excitatory 
motoneurons results in the release of excitatory 
neuromediators (acetylcholine, substance P) onto smooth 
muscle fibers causing circumferential contraction of the 
circular muscle layer upstream of the bolus.  Activation of 
descending interneurons and inhibitory motoneurons 
results in the release of inhibitory neuromediators (VIP - 
vasoactive intestinal polypeptide, nitric oxide) causing 
relaxation of circular muscle downstream of the bolus.    
 
The basic electrical rhythms in the gut are fairly 
constant and characterized by slow waves,  
rhythmical oscillations of the smooth muscle 
membrane potential, which are responsible for the 
contractions of the muscles. These threshold events 
represent true smooth muscle action potentials. Spikes are 
not essential for excitation–contraction coupling in GI 
smooth muscle, but their occurrence is associated with 
more forceful contractions.  Smooth muscle cells lack the 
ionic mechanisms necessary to regenerate electrical 
slow waves. The search for the origin of rhythmicity in 
intestinal contraction has identified pacemaker regions 
of the slow waves located at the myenteric and 
submucosal borders of circular muscles and contains a 
network of cells known as the interstitial cells of 
Cajal.2 These interstitial cells of Cajal are distinctive 
populations of muscle-like cells. They make contact 
with each other and with muscle cells and nerve 
terminals and function as pacemakers in 
gastrointestinal muscles by initiating rhythmic 
electrical activity. Excitatory agonists, such as ACh, 
stimulate intestinal phasic motor activity by increasing 
the amplitude of slow wave activity and thereby 
enhancing spike potential activity, resulting in a 
contractile wave passing down the gut. Inhibitory 
transmitters, such as VIP or NO,  causes reduction of 
the amplitudes of slow waves and the membrane 
potential at the peak of the slow wave is too far below 
threshold for an action potential to occur and the 
smooth muscle relaxes.  Besides acetylcholine, 
vasoactive intestinal peptide and nitric oxide, other 
chemical agents may act as modulator of 
gastrointestinal function acting at different levels, 
smooth muscle cells, ICCs, nerve terminals, 
interneural synapses. So, the gastrointestinal smooth 
muscle contractility  is regulated not by one or another 
of the transmitters, but by at least two and often more, 
pharmacologically coupled and working in close 
coordination. These complex functional interactions 
have some variations depending on the species, organ 
system and region of the gut. 
 
In addition, there is evidence that the ENS is 
involved in the control of immune and inflammatory 
processes throughout the gut. Immuno-neural 
integration progresses sequentially, beginning with 
immune detection followed by signal transfer to 
enteric neural microcircuits, followed by neural 
interpretation and then selection of a specific neural 
program of coordinated mucosal secretion and motor 
propulsion that effectively clears the antigenic threat 
from the intestinal lumen.   
 
Thus, it is not surprising that any damage to ENS 
circuitries results in a wide array of gut disorders, 
including motor impairments, which are characterized 
by high morbidity, with a markedly compromised 
patient’s quality of life and occasional fatal outcomes. 
Besides a few exceptions, the mechanisms through 
which neural diseases cause gastrointestinal 
dysfunction, including motor abnormalities, remain 
poorly understood.  
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Among the plethora of neural systems which control 
GI motility I wish to focus on the dopaminergic system 
since it seems to be a major candidate for the impairment 
of GI function frequently encountered by patients affected 
by Parkinson’s disease (PD).3  
 
Parkinson’s disease is the second most common 
neurodegenerative disease after Alzheimer’s disease. It is 
well-known that PD is an extrapyramidal motor disorder 
which is caused by the massive loss of dopaminergic 
neurons in the substantia nigra pars compacta. 
Nevertheless, it has become increasingly evident in recent 
years that Parkinson’s disease is a multicentric 
neurodegenerative process that affects several neuronal 
structures outside the substantia nigra, among which is the 
enteric nervous system.4 Remarkably, recent reports have 
shown that the lesions in the enteric nervous system occur 
at a very early stage of the disease, even before the 
involvement of the central nervous system, and 
abnormalities or disturbances in function at virtually all 
levels of the GI system have been identified.5 Weight loss, 
dental deterioration, salivary excess, dysphagia, impaired 
gastric emptying, decreased bowel movement frequency, 
and difficulty with the act of defecation itself all may 
occur in the setting of PD.3 This led to the postulate that 
the enteric nervous system could be critical in the 
pathophysiology of Parkinson’s disease, and  that the 
pathological alterations within the enteric nervous system 
could be involved in the gastrointestinal dysfunction 
frequently encountered by Parkinsonian patients.  In 
addition to being the source of significant clinical 
symptoms and dysfunction in individuals with PD, it has 
now been suggested that the ENS may actually be the port 
of entry of the pathologic process that eventually 
culminates in the clinical picture of PD.5 Animal models of 
PD are essential tools with which to identify novel 
therapeutic targets and test potential therapies. However, 
appropriate animal models to investigate in depth the GI 
impairment in PD is lacking due to the scarce information 
of the physiological role of DA in the gut, necessary also 
to solve the respective roles of intrinsic and extrinsic 
innervations in GI dysfunction.  
 
Although the gut contains dopamine,6 this 
catecholamine has only recently been confirmed as an 
intrinsic neurotransmitter of the enteric nervous system 
(ENS).7,8  In fact, enteric dopaminergic neurons, which 
express tyrosine hydroxylase (TH) and the dopamine 
transporter (DAT) but lack dopamine β-hydroxylase, 
enzyme that converts dopamine to norepinephrine, have 
been identified in mouse, guinea pig8 and human.7 In 
mouse, all five classes of dopamine receptors D1-like 
family, including D1 and D5 receptors, and D2-like family, 
including D2, D3, and D4 receptors have been identified 
throughout the digestive tract.9 Dopamine receptors appear 
decreased in the myenteric plexus of PD patients. 
However, the function of enteric dopaminergic 
neurons in the regulation of GI motility is still far from 
clear and the mechanism of dopamine action and 
location of dopamine receptors are controversial. 
Moreover, conclusions regarding the role of dopamine 
in modulating GI tract motility have been confounded 
by the ability of dopamine agonists to activate 
adrenergic receptors.  Therefore, the role of DA in 
bowel motility needs to be identified and considered 
for potential treatments of GI dysfunction in PD.  
 
 
 
Figure 1- Typical recording of muscular tension developed 
in mouse ileum under control conditions and following D1 
receptor blockade. Arrows indicate the initiation of 
cholinergic neural stimulation.  
Note that smooth muscle tone, spontaneous phasic 
contraction amplitude and neurally-induced contraction 
were enhanced following D1 receptor blockade indicating 
that dopamine-mediated inhibitory input is tonically 
supplied to mouse ileum. 
 
 
Intestinal motility can be studied in vitro using the 
organ bath technique, which allow the  recording, as a 
change in isometric tension, of spontaneous contractile 
activity and neurally evoked responses. Thus, using 
such an approach we can distinguish effects of various 
chemical agents on GI motility which occur through 
modulation of the enteric nervous system from effects 
mediated by receptors located on smooth muscle cells. 
Our analysis of the effects of dopamine on mouse 
ileum contractility indicates that intestinal muscle is 
under basal inhibitory control by a dopamine-mediated 
system (Fig. 1).  D1 receptors play a major role being 
located both at postjunctional level and at 
prejunctional level, inhibiting acetylcholine release 
from enteric motor neurons.10 We have clarified 
whether the source of dopamine is from neural or non-
neural cells. Moreover, the results presented showed 
that there is an agonistic interaction of the 
dopaminergic receptor subtypes (D1 and D2 receptors) 
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in the regulation intestinal contractility. It remains unclear 
why the loss of DA neurons in the gut determines 
inhibition of contractility and constipation. Furthermore, 
data are sparse for the role of the enteric dopaminergic 
nervous system in the pathophysiology of the 
gastrointestinal symptoms including the relative 
contribution of D1 and D2 receptors in the presence of 
different DA concentration (which varies from the healthy 
state to the disease) and the eventual changes in the pattern 
of expression of DA receptor subtypes following DA 
denervation. Moreover, the possibility that more than one 
neurotransmitter system is actually affected might be 
considered.   
 
In conclusion, investigative evidence and emerging 
concepts implicate dysfunction in the nervous system as a 
significant factor underlying patient symptoms in 
functional gastrointestinal disorders. The future challenges 
are, then, to properly understand the molecular and cellular 
changes that underlie enteric neuropathies, to utilize 
knowledge of the normal neurochemistry, pharmacology 
and physiology of the ENS to devise strategies to treat 
disorders of motility and to develop effective therapeutic 
compounds. 
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